Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIP, Nimotuzumab, and Triprilimab in Locally Advanced Penile Cancer
NCT04475016Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2020
- Primary completion
- May 2022
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab, toripalimab in penile cancer, sponsored by Sun Yat-sen University. Started Aug 2020; status: completed.
02
Drugs
nimotuzumabtoripalimab
03
Conditions
penile cancer
Beyond the preview
Go deeper on NCT04475016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04475016.